Vanda Pharmaceuticals (VNDA) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q4 2025 value amounting to -$141.2 million.
- Vanda Pharmaceuticals' Income towards Parent Company fell 277518.32% to -$141.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$220.5 million, marking a year-over-year decrease of 106663.14%. This contributed to the annual value of -$220.5 million for FY2025, which is 106652.91% down from last year.
- Vanda Pharmaceuticals' Income towards Parent Company amounted to -$141.2 million in Q4 2025, which was down 277518.32% from -$22.6 million recorded in Q3 2025.
- Vanda Pharmaceuticals' Income towards Parent Company's 5-year high stood at $9.6 million during Q2 2021, with a 5-year trough of -$141.2 million in Q4 2025.
- Over the past 5 years, Vanda Pharmaceuticals' median Income towards Parent Company value was -$1.1 million (recorded in 2023), while the average stood at -$9.9 million.
- As far as peak fluctuations go, Vanda Pharmaceuticals' Income towards Parent Company surged by 185646.26% in 2021, and later crashed by 305777.78% in 2024.
- Over the past 5 years, Vanda Pharmaceuticals' Income towards Parent Company (Quarter) stood at $7.1 million in 2021, then fell by 2.96% to $6.9 million in 2022, then tumbled by 134.71% to -$2.4 million in 2023, then tumbled by 105.44% to -$4.9 million in 2024, then tumbled by 2775.18% to -$141.2 million in 2025.
- Its Income towards Parent Company was -$141.2 million in Q4 2025, compared to -$22.6 million in Q3 2025 and -$27.2 million in Q2 2025.